Definium Therapeutics (DFTX) EPS (Weighted Average and Diluted) (2020 - 2026)
Definium Therapeutics (DFTX) reported EPS (Weighted Average and Diluted) of -$0.71 for Q1 2026, down 102.86% year-over-year from $24.85 in Q1 2025, and down 42.0% on a QoQ basis from -$0.5 in Q4 2025.
Definium Therapeutics (DFTX) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.71 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) fell 102.86% year-over-year to -$0.71 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.49 (down 91.54% YoY) and the FY2025 annual result came in at -$2.06, down 33.77% from the prior year.
- EPS (Weighted Average and Diluted) eased to -$0.71 in Q1 2026 per DFTX's latest filing, from -$0.5 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.02 in Q4 2022 and bottomed at -$1.14 in Q1 2024.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.56 (2022), against an average of -$0.54.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) soared 96.61%; it then tumbled 2850.0% in 2023.
- Tracing DFTX's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.02 in 2022, then plunged by 2850.0% to -$0.59 in 2023, then rose by 28.81% to -$0.42 in 2024, then declined by 19.05% to -$0.5 in 2025, then slumped by 42.0% to -$0.71 in 2026.
- Per Business Quant, the three latest DFTX EPS (Weighted Average and Diluted) figures stand at -$0.71 (Q1 2026), -$0.5 (Q4 2025), and -$0.78 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | -0.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.71 |
| Dec 31, 2025 | -0.50 |
| Sep 30, 2025 | -0.78 |
| Jun 30, 2025 | -0.50 |
| Mar 31, 2025 | -0.35 |
| Dec 31, 2024 | -0.42 |
| Sep 30, 2024 | -0.27 |
| Jun 30, 2024 | -0.26 |
| Mar 31, 2024 | -1.14 |
| Dec 31, 2023 | -0.59 |
| Sep 30, 2023 | -0.45 |
| Jun 30, 2023 | -0.76 |
| Mar 31, 2023 | -0.65 |
| Dec 31, 2022 | -0.02 |
| Sep 30, 2022 | -0.56 |
| Jun 30, 2022 | -0.60 |
| Mar 31, 2022 | -0.66 |
| Dec 31, 2021 | -0.59 |
| Sep 30, 2021 | -0.61 |
| Jun 30, 2021 | -0.11 |
| Mar 31, 2021 | -0.04 |
| Sep 30, 2020 | -0.03 |
| Jun 30, 2020 | -0.02 |
| Mar 31, 2020 | -0.03 |